AC Immune SA
ACIU
$2.79
$0.010.18%
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 91.38% | 95.15% | 95.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 91.38% | 95.15% | 95.15% |
| Cost of Revenue | -- | -- | 8.88% | 13.02% | 13.02% |
| Gross Profit | -- | -- | 20.30% | 16.54% | 16.54% |
| SG&A Expenses | -- | -- | -3.56% | 3.12% | 3.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 93.54% | 93.64% | 93.64% |
| Total Operating Expenses | -- | -- | 7.25% | 12.48% | 12.48% |
| Operating Income | -- | -- | 14.48% | 9.31% | 9.31% |
| Income Before Tax | -- | -- | 14.13% | 5.99% | 5.99% |
| Income Tax Expenses | -- | -- | -24.44% | -56.41% | -56.41% |
| Earnings from Continuing Operations | -- | -- | 14.13% | 5.99% | 5.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 14.13% | 5.99% | 5.99% |
| EBIT | -- | -- | 14.48% | 9.31% | 9.31% |
| EBITDA | -- | -- | 14.67% | 9.27% | 9.27% |
| EPS Basic | -- | -- | 19.42% | 16.10% | 16.10% |
| Normalized Basic EPS | -- | -- | 19.42% | 16.09% | 16.09% |
| EPS Diluted | -- | -- | 18.34% | 14.99% | 14.99% |
| Normalized Diluted EPS | -- | -- | 19.33% | 16.00% | 16.00% |
| Average Basic Shares Outstanding | -- | -- | 8.23% | 12.47% | 12.47% |
| Average Diluted Shares Outstanding | -- | -- | 8.50% | 12.76% | 12.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |